Articles by Jill Wechsler - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Jill Wechsler

Product Analysis Key to Biosimilar Development

Manufacturing and in-depth characterization provide basis for demonstrating product equivalence.
Nov 1, 2012

Manufacturing and in-depth characterization provide basis for demonstrating product equivalence.

New Era for Generic Drugs

User fees aim to speed approvals and support inspections.
Oct 1, 2012

User fees aim to speed approvals and support inspections.

Campaign Mounts to Curb Counterfeit Drugs

Manufacturers and regulators struggle to control phony versions of crucial medicines.
Sep 1, 2012

Manufacturers and regulators struggle to control phony versions of crucial medicines.

Healthcare Reform and Next Steps for BioPharma

Now that the Supreme Court has upheld the Affordable Care Act, what's next for biopharma?
Aug 1, 2012

Now that the Supreme Court has upheld the Affordable Care Act, what's next for biopharma?

FDA User-Fee Legislation

Import controls and risk strategies aim to promote quality and spur new drug development.
Aug 1, 2012

Import controls and risk strategies aim to promote quality and spur new drug development.

Commentary: International AIDS Conference Highlights ARV Advances

Jul 31, 2012

Biotech Innovation Gains Support in Washington

Multiple initiatives are moving forward to maintain US leadership in biopharm R&D.
Jul 1, 2012

Multiple initiatives are moving forward to maintain US leadership in biopharm R&D.

Commentary: Healthcare Reform is Ruled Constitutional

What's next for biotech?
Jun 29, 2012

In a 5–4 vote, the Supreme Court has ruled in favor of the Constitutionality of the Affordable Care Act.

Interview with FDA: Adopting New Strategies to Oversee Global Economy

In a special anniversary interview, Washington Editor Jill Wechsler speaks with with FDA Deputy Commissioner Deborah Autor about where the agency is headed.
Jun 1, 2012

In a special anniversary interview, Washington Editor Jill Wechsler speaks with with FDA Deputy Commissioner Deborah Autor about where the agency is headed.

ADVERTISEMENT

ADVERTISEMENT

Click here